Effectiveness of antiretroviral therapy in individuals who for economic reasons were switched from a once-daily single-tablet regimen to a triple-tablet regimen
To assess the impact on virological outcomes of a switch from branded single-tablet regimen (STR) including tenofovir, efavirenz, and emtricitabine (STR-TEE) to generic triple-tablet regimen (TTR), including tenofovir, efavirenz, and lamivudine (TTR-TEL), which was implemented on April 1, 2011 to ob...
Uloženo v:
| Vydáno v: | Journal of acquired immune deficiency syndromes (1999) Ročník 66; číslo 4; s. 407 |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.08.2014
|
| Témata: | |
| ISSN: | 1944-7884, 1944-7884 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | To assess the impact on virological outcomes of a switch from branded single-tablet regimen (STR) including tenofovir, efavirenz, and emtricitabine (STR-TEE) to generic triple-tablet regimen (TTR), including tenofovir, efavirenz, and lamivudine (TTR-TEL), which was implemented on April 1, 2011 to obtain economic savings.
From the Capital Region of Denmark (covering two-thirds of the Danish HIV patients), we included combination antiretroviral therapy (cART)-naive patients who administered STR-TEE from April 1, 2010 to March 31, 2011 (n = 111) or TTR-TEL from April 1, 2011 to March 31, 2012 (n = 56) and cART-experienced HIV patients who were on STR-TEE from April 1, 2010 (n = 356) or were switched from STR-TEE to TTR-TEL after April 1, 2011 (n = 512). We estimated the fraction with detectable HIV-RNA, development of the 184V/I resistance mutations, and time to switch of cART. Approximately 96.2% of cART-experienced patients on STR-TEE were shifted to TTR-TEL after April 1, 2011. For the naive STR-TEE and TTR-TEL patients, the fractions with detectable HIV-RNA at week 48 were 7.0% and 8.3% and for the cART experienced 4.0% and 4.4%, respectively. The 184V/I resistance mutation was detected in 1 cART-experienced patient on TTR-TEL with virological failure. The risk of switch to a new cART regimen was slightly increased in the cART-experienced population (difference in 1-year risk: 1.5%; 95% confidence interval: -2.4% to 5.4%).
In settings comparable with the Danish health care system, the estimated economic savings from a switch from STR-TEE to TTR-TEL can be realized with negligible short-term risk of adverse outcomes. |
|---|---|
| AbstractList | To assess the impact on virological outcomes of a switch from branded single-tablet regimen (STR) including tenofovir, efavirenz, and emtricitabine (STR-TEE) to generic triple-tablet regimen (TTR), including tenofovir, efavirenz, and lamivudine (TTR-TEL), which was implemented on April 1, 2011 to obtain economic savings.
From the Capital Region of Denmark (covering two-thirds of the Danish HIV patients), we included combination antiretroviral therapy (cART)-naive patients who administered STR-TEE from April 1, 2010 to March 31, 2011 (n = 111) or TTR-TEL from April 1, 2011 to March 31, 2012 (n = 56) and cART-experienced HIV patients who were on STR-TEE from April 1, 2010 (n = 356) or were switched from STR-TEE to TTR-TEL after April 1, 2011 (n = 512). We estimated the fraction with detectable HIV-RNA, development of the 184V/I resistance mutations, and time to switch of cART. Approximately 96.2% of cART-experienced patients on STR-TEE were shifted to TTR-TEL after April 1, 2011. For the naive STR-TEE and TTR-TEL patients, the fractions with detectable HIV-RNA at week 48 were 7.0% and 8.3% and for the cART experienced 4.0% and 4.4%, respectively. The 184V/I resistance mutation was detected in 1 cART-experienced patient on TTR-TEL with virological failure. The risk of switch to a new cART regimen was slightly increased in the cART-experienced population (difference in 1-year risk: 1.5%; 95% confidence interval: -2.4% to 5.4%).
In settings comparable with the Danish health care system, the estimated economic savings from a switch from STR-TEE to TTR-TEL can be realized with negligible short-term risk of adverse outcomes. To assess the impact on virological outcomes of a switch from branded single-tablet regimen (STR) including tenofovir, efavirenz, and emtricitabine (STR-TEE) to generic triple-tablet regimen (TTR), including tenofovir, efavirenz, and lamivudine (TTR-TEL), which was implemented on April 1, 2011 to obtain economic savings.BACKGROUNDTo assess the impact on virological outcomes of a switch from branded single-tablet regimen (STR) including tenofovir, efavirenz, and emtricitabine (STR-TEE) to generic triple-tablet regimen (TTR), including tenofovir, efavirenz, and lamivudine (TTR-TEL), which was implemented on April 1, 2011 to obtain economic savings.From the Capital Region of Denmark (covering two-thirds of the Danish HIV patients), we included combination antiretroviral therapy (cART)-naive patients who administered STR-TEE from April 1, 2010 to March 31, 2011 (n = 111) or TTR-TEL from April 1, 2011 to March 31, 2012 (n = 56) and cART-experienced HIV patients who were on STR-TEE from April 1, 2010 (n = 356) or were switched from STR-TEE to TTR-TEL after April 1, 2011 (n = 512). We estimated the fraction with detectable HIV-RNA, development of the 184V/I resistance mutations, and time to switch of cART. Approximately 96.2% of cART-experienced patients on STR-TEE were shifted to TTR-TEL after April 1, 2011. For the naive STR-TEE and TTR-TEL patients, the fractions with detectable HIV-RNA at week 48 were 7.0% and 8.3% and for the cART experienced 4.0% and 4.4%, respectively. The 184V/I resistance mutation was detected in 1 cART-experienced patient on TTR-TEL with virological failure. The risk of switch to a new cART regimen was slightly increased in the cART-experienced population (difference in 1-year risk: 1.5%; 95% confidence interval: -2.4% to 5.4%).METHODS AND FINDINGSFrom the Capital Region of Denmark (covering two-thirds of the Danish HIV patients), we included combination antiretroviral therapy (cART)-naive patients who administered STR-TEE from April 1, 2010 to March 31, 2011 (n = 111) or TTR-TEL from April 1, 2011 to March 31, 2012 (n = 56) and cART-experienced HIV patients who were on STR-TEE from April 1, 2010 (n = 356) or were switched from STR-TEE to TTR-TEL after April 1, 2011 (n = 512). We estimated the fraction with detectable HIV-RNA, development of the 184V/I resistance mutations, and time to switch of cART. Approximately 96.2% of cART-experienced patients on STR-TEE were shifted to TTR-TEL after April 1, 2011. For the naive STR-TEE and TTR-TEL patients, the fractions with detectable HIV-RNA at week 48 were 7.0% and 8.3% and for the cART experienced 4.0% and 4.4%, respectively. The 184V/I resistance mutation was detected in 1 cART-experienced patient on TTR-TEL with virological failure. The risk of switch to a new cART regimen was slightly increased in the cART-experienced population (difference in 1-year risk: 1.5%; 95% confidence interval: -2.4% to 5.4%).In settings comparable with the Danish health care system, the estimated economic savings from a switch from STR-TEE to TTR-TEL can be realized with negligible short-term risk of adverse outcomes.CONCLUSIONSIn settings comparable with the Danish health care system, the estimated economic savings from a switch from STR-TEE to TTR-TEL can be realized with negligible short-term risk of adverse outcomes. |
| Author | Helleberg, Marie Nielsen, Lars N Kronborg, Gitte Mathiesen, Lars R Gerstoft, Jan Obel, Niels Engsig, Frederik N |
| Author_xml | – sequence: 1 givenname: Frederik N surname: Engsig fullname: Engsig, Frederik N organization: Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Denmark; †Department of Microbiology Diagnostics and Virology, Statens Serum Institut, Copenhagen, Denmark; ‡Department of Infectious Diseases, Copenhagen University Hospital, Nordsjælland Hospital, Denmark; and §Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark – sequence: 2 givenname: Jan surname: Gerstoft fullname: Gerstoft, Jan – sequence: 3 givenname: Marie surname: Helleberg fullname: Helleberg, Marie – sequence: 4 givenname: Lars N surname: Nielsen fullname: Nielsen, Lars N – sequence: 5 givenname: Gitte surname: Kronborg fullname: Kronborg, Gitte – sequence: 6 givenname: Lars R surname: Mathiesen fullname: Mathiesen, Lars R – sequence: 7 givenname: Niels surname: Obel fullname: Obel, Niels |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24984188$$D View this record in MEDLINE/PubMed |
| BookMark | eNplkMFKAzEQQINUrK3-gUiOXrYmaba7OZZStVAQQc8lm0zayG5Sk7Slf-OnGrBCwWFgBt6bGZgB6jnvAKE7SkaUiOrxbboYkfOgQlygayo4L6q65r2zvo8GMX5mZcK5uEJ9xkXNaV1fo--5MaCS3YODGLE3WLpkA6Tg9zbIFqcNBLk9Yutyaru3eifbiA8bj40PGJR3vrMKB5DRuwwgAI4Hm9QGNDbBd1hi7xQUWtr2iKN16xaKJJsWUp5a2w4cTj5bKdjtP3SDLk0-CLenOkQfT_P32UuxfH1ezKbLQnFaiULJhjBZGxDMlBVhutKirDSZGFoqIIqoZiwFpQ2YcSM0JyWtM9eMNDxLjA3Rw-_ebfBfO4hp1dmooG2lA7-LK1pyNuGiZFVW70_qrulAr7bBdjIcV39fZT_p54A5 |
| CitedBy_id | crossref_primary_10_1093_jac_dkz439 crossref_primary_10_12998_wjcc_v7_i14_1814 crossref_primary_10_1136_bmjopen_2020_046212 crossref_primary_10_1111_hiv_70028 crossref_primary_10_1016_j_therap_2017_10_001 crossref_primary_10_1177_2325958218822304 crossref_primary_10_1177_2050312118816919 crossref_primary_10_1089_aid_2021_0122 crossref_primary_10_1371_journal_pone_0239704 crossref_primary_10_1097_QAD_0000000000000424 crossref_primary_10_1097_QCO_0000000000000106 crossref_primary_10_1002_jia2_25758 crossref_primary_10_1016_j_healthpol_2018_01_002 crossref_primary_10_1097_MD_0000000000001677 crossref_primary_10_1111_hiv_12426 crossref_primary_10_1111_hiv_12701 crossref_primary_10_1007_s40801_016_0070_9 crossref_primary_10_1371_journal_pone_0262533 crossref_primary_10_1177_1078345818792843 crossref_primary_10_1089_apc_2015_0199 crossref_primary_10_1111_bcpt_12585 crossref_primary_10_1111_hiv_12578 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1097/QAI.0000000000000199 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1944-7884 |
| ExternalDocumentID | 24984188 |
| Genre | Journal Article |
| GeographicLocations | Denmark |
| GeographicLocations_xml | – name: Denmark |
| GroupedDBID | --- .-D .XZ .Z2 01R 0R~ 1J1 354 40H 4Q1 4Q2 4Q3 5GY 5RE 5VS 77Y 7O~ 8L- AAAAV AAAXR AAGIX AAHPQ AAIQE AAJCS AAMOA AARTV AASOK AAXQO ABBUW ABDIG ABIVO ABXVJ ABZAD ACCJW ACDDN ACEWG ACGFO ACGFS ACIJW ACILI ACOAL ACPRK ACWDW ACWRI ACXNZ ACZKN ADGGA ADHPY AE3 AE6 AEETU AFDTB AFEXH AFNMH AFRAH AFUWQ AGINI AHMBA AHOMT AHQNM AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJZMW ALKUP ALMA_UNASSIGNED_HOLDINGS AMJPA AMNEI BKOMP BOYCO BQLVK BYPQX C45 CGR CS3 CUY CVF DIWNM DUNZO E.X EBS ECM EIF EJD EX3 F2K F2L F2M F2N F5P FCALG FL- FRJ FRP H0~ HZ~ IKREB IKYAY IN~ JK3 JK8 K8S KD2 KMI L-C NPM N~7 N~B O9- OAG OAH ODMTH OHH OHYEH OLG OLH OLU OLV OLY OLZ OPUJH OVD OVDNE OVIDH OVLEI OWV OWX OWY OWZ OXXIT P2P PQQKQ RLZ RXW S4R S4S TAE TEORI V2I VVN W2D W3M WOQ WOW X3V X3W XYM YOC ZZMQN 7X8 ABPXF ADKSD |
| ID | FETCH-LOGICAL-c4179-cab02a8fe92f5702d7d957d06f15ce0c0cb3a911bef3b9d4051857dd20b406f22 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 28 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000339012300015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1944-7884 |
| IngestDate | Mon Sep 08 12:20:19 EDT 2025 Thu Apr 03 07:05:59 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4179-cab02a8fe92f5702d7d957d06f15ce0c0cb3a911bef3b9d4051857dd20b406f22 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 24984188 |
| PQID | 1542649527 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1542649527 pubmed_primary_24984188 |
| PublicationCentury | 2000 |
| PublicationDate | 2014-August-1 |
| PublicationDateYYYYMMDD | 2014-08-01 |
| PublicationDate_xml | – month: 08 year: 2014 text: 2014-August-1 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of acquired immune deficiency syndromes (1999) |
| PublicationTitleAlternate | J Acquir Immune Defic Syndr |
| PublicationYear | 2014 |
| SSID | ssj0016449 |
| Score | 2.2575552 |
| Snippet | To assess the impact on virological outcomes of a switch from branded single-tablet regimen (STR) including tenofovir, efavirenz, and emtricitabine (STR-TEE)... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 407 |
| SubjectTerms | Adult Anti-HIV Agents - administration & dosage Anti-HIV Agents - economics Anti-HIV Agents - therapeutic use CD4 Lymphocyte Count Denmark - epidemiology Drug Administration Schedule Drug Combinations Female HIV Infections - drug therapy HIV Infections - epidemiology Humans Male Middle Aged Treatment Outcome Viral Load |
| Title | Effectiveness of antiretroviral therapy in individuals who for economic reasons were switched from a once-daily single-tablet regimen to a triple-tablet regimen |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/24984188 https://www.proquest.com/docview/1542649527 |
| Volume | 66 |
| WOSCitedRecordID | wos000339012300015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvRvC6GDdJd_ckIooeLAoKvZVkHxjQpDbR4r_xpzqTpAqCIJhDLslCmExmv8zMNx9jR9baQEmRcKuV4xFGA54mgeVKO9_zkoRqfC02Ift9NRjo2zbhVrZtldOYWAdqWxjKkR_jVo97t46FPB29cFKNoupqK6ExyzohQhnyajn4riLgXq_rqnIUUddcNKXOaXl8d3bdjC6cHs30119AZr3ZXC7_9zFX2FILM-Gs8YtVNuPyNbZw0xbS19lHM7W4DXVQeEALY_SrKMMwxpUNL-sdshyyL85WCZPHAhDmgmv5zEA97ei4MHFjB-UkIyewQKQVSIAokdwm2dM7UEriyfGKmFoVkBzEs8uhKvCuakzJ_h-XNtjD5cX9-RVvxRq4IREzbpI0EInyTgsfy0BYaXUsbdDzJ7FxgQlMGiYYWVPnw1RbxIk0hcpaEaSIKbwQm2wuL3K3zSAO0VGsrEf7oCmlcpGM0YFCYRBumV6XHU5tP8SPgSocSe6K13L4bf0u22pe4HDUTO0Y4n-mik6U2vnD6l22iMAoahr99ljHo4XdPps3b1VWjg9qL8Nz__bmE4V13yY |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effectiveness+of+antiretroviral+therapy+in+individuals+who+for+economic+reasons+were+switched+from+a+once-daily+single-tablet+regimen+to+a+triple-tablet+regimen&rft.jtitle=Journal+of+acquired+immune+deficiency+syndromes+%281999%29&rft.au=Engsig%2C+Frederik+N&rft.au=Gerstoft%2C+Jan&rft.au=Helleberg%2C+Marie&rft.au=Nielsen%2C+Lars+N&rft.date=2014-08-01&rft.issn=1944-7884&rft.eissn=1944-7884&rft.volume=66&rft.issue=4&rft.spage=407&rft_id=info:doi/10.1097%2FQAI.0000000000000199&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1944-7884&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1944-7884&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1944-7884&client=summon |